The Vanguard Group, Inc. recently announced the acquisition of new stake in Sigilon Therapeutics Inc. (NASDAQ:SGTX). The institutional investor has increased its shareholding in the Healthcare company by 22.83% to 0.29 million shares with purchase of 54770.0 shares. This fresh investment now brings its stake to 0.91% valued currently at $0.1 million. In addition, Geode Capital Management LLC raised its holdings by 1134.0 to 0.12 million shares.
With over 0.51 million Sigilon Therapeutics Inc. (SGTX) shares trading Friday and a closing price of $0.46 on the day, the dollar volume was approximately $0.23 million. The shares have shown a negative half year performance of -45.88% and its price on 01/13/23 gained nearly 25.61%. Currently, there are 32.40M common shares owned by the public and among those 28.13M shares have been available to trade.
Will You Miss Out On This Growth Stock Boom?
A new megatrend in the fintech market is well underway. Mobile payments are projected to boom into a massive $12 trillion market by 2028. According to Motley Fool this growth stock could "deliver huge returns." Not only in the immediate future but also over the next decade. Especially since the man behind this company is a serial entrepreneur who has been wildly successful over the years.
And this is just one of our
5 Best Growth Stocks To Own For 2023.
Sponsored
Insiders at the company have transacted a total of 0 times over the past 12 months, according to data filed with the U.S. Securities and Exchange Commission (SEC). 0 of these insider trades were purchases, accounting for 0 shares. Insider sales of the common stock occurred on 0 occasions, with total insider shares sold totaling 0 shares.
The top 3 mutual fund holders in Sigilon Therapeutics Inc. are Canada Pension Plan, BlackRock Health Sciences Trust I, and Fidelity Growth Company Fund. Canada Pension Plan owns 1.49 million shares of the company’s stock, all valued at over $0.52 million. The company sold 10162.0 shares recently to bring their total holdings to about 4.58% of the shares outstanding. Fidelity Growth Company Fund sold 9144.0 shares to bring its total holdings to over 0.38 million shares at a value of $0.13 million. Fidelity Growth Company Fund now owns shares totaling to 1.18% of the shares outstanding.
However, the script later moved the day high at 0.4874, up 25.61%. The company’s stock has a 5-day price change of 29.36% and -4.56% over the past three months. SGTX shares are trading 31.43% year to date (YTD), with the 12-month market performance down to -79.91% lower. It has a 12-month low price of $0.29 and touched a high of $2.29 over the same period. SGTX has an average intraday trading volume of 48.13K shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by 37.81%, 15.32%, and -36.17% respectively.
Institutional ownership of Sigilon Therapeutics Inc. (NASDAQ: SGTX) shares accounts for 52.20% of the company’s 32.40M shares outstanding. Mutual fund holders own 11.04%, while other institutional holders and individual stakeholders account for 6.91% and 0.31% respectively.
It has a market capitalization of $11.90M. The earnings-per-share (ttm) stands at -$1.69. Price movements for the stock have been influenced by the stock’s volatility, which stands at 15.62% over the week and 10.67% over the month.
Analysts forecast that Sigilon Therapeutics Inc. (SGTX) will achieve an EPS of -$0.42 for the current quarter, -$0.45 for the next quarter and -$1.37 for 2023. The lowest estimate earnings-per-share for the quarter is -$0.44 while analysts give the company a high EPS estimate of -$0.41. Comparatively, EPS for the current quarter was -$0.63 a year ago. Earnings per share for the fiscal year are expected to decrease by -39.80%, and 15.90% over the next financial year.
Looking at the support for the SGTX, a number of firms have released research notes about the stock. Jefferies stated their Hold rating for the stock in a research note on November 30, 2021, with the firm’s price target at $15-$4. BTIG Research coverage for the Sigilon Therapeutics Inc. (SGTX) stock in a research note released on October 29, 2021 offered a Buy rating with a price target of $14. Jefferies was of a view on August 02, 2021 that the stock is Buy, while Morgan Stanley gave the stock Equal-Weight rating on December 29, 2020, issuing a price target of $45. Jefferies on their part issued Buy rating on December 29, 2020.
